<DOC>
	<DOCNO>NCT02384408</DOCNO>
	<brief_summary>Healthy postmenopausal woman , amenorrheic 1-10 year , age 45-60 year use follicle stimulate hormone &gt; 30 mille-International unit/milliliters ( mIU/mL ) , participate study . All woman inform physician risk possible benefit Hormone Replacement Therapy ( HRT ) . The continuous combined treatment drospirenone 2 mg 17β-estradiol 1 mg tibolone 1.25 mg administer 24-week period . Transvaginal ultrasound perform evaluate thickness endometrium baseline . At study end-point , endometrial biopsy perform Pipelle endometrial sampler examine histological immunohistochemical parameter . Immunohistochemical detection Bcl-2 protein , estrogen progesterone receptor perform stroma glandular epithelium .</brief_summary>
	<brief_title>Hormone Replacement Therapy Postmenopausal Endometrium</brief_title>
	<detailed_description>Subjects Healthy postmenopausal woman , amenorrheic 1-10 year , age 45-60 year use follicle stimulate hormone &gt; 30 mille-International unit/milliliters ( mIU/mL ) , participate study . All woman inform trial sign informed consent document , eligibility determine base medical history , general physical gynecological examination . All woman inform physician risk possible benefit Hormone Replacement Therapy ( HRT ) . Upon inclusion , Transvaginal ultrasound ( TV-US ) perform evaluate thickness endometrium baseline . At study end-point , endometrial biopsy perform Pipelle endometrial sampler examine histological immunohistochemical parameter . Vital sign , blood pressure , weight , Pap smear , mammography , routine clinical chemistry assay ( include , cholesterol , high density lipoprotein cholesterol , low density lipoprotein cholesterol , triglyceride ) hematology also evaluate screen . Treatment Groups Of 100 woman initially evaluate , 32 meet inclusion exclusion criterion , eight refuse participate , give final total 60 patient inclusion study . The sixty postmenopausal woman randomly allocate three group : Group I : control group comprise 20 patient ( hormonal treatment ) ; Group II : also comprise 20 patient , continuous combine treatment drospirenone 2 mg 17β-estradiol 1 mg ( DRSP/E2 ) administer daily ; Group III : also comprise 20 patient , treatment tibolone 1.25 mg ( Tib ) administer daily . All treatment administer 24-week period . DRSP/E2 purchase `` Bayer Schering Pharma™ '' , Brazil Tib `` Biolab™ '' , Brazil . The duration treatment 6 cycle , last period 28 day ( conduct total 24 week ) . Randomization do aid computer software order prevent bias selection process . Objective : A prospective randomized control trial conduct evaluate effect low dose tibolone estradiol/drospirenone histology , expression estrogen ( ER ) progesterone receptor ( PR ) Bcl-2 protein , endometrium postmenopausal woman . The effect endometrial thickness determine Transvaginal Ultrasound ( TV-USG ) study baseline 6 cycle treatment woman participant . Scans perform real-time scanner , `` Hitachi 405 '' ultrasound system equip 5.0-megahertz ( MHz ) vaginal transducer , `` Vale Sapucai University '' . An endometrial thickness &lt; 4 millimeter ( mm ) interpret support diagnosis endometrial cancer . Endometrial biopsy sample performed end treatment course use `` Pipelle Curette '' de Cornier , place high upper fundus uterus . An aliquot endometrial sample push pipette polypropylene vial . The vial capped , immediately frozen , stored -20º Celsius ship dry ice Department Pathology `` Vale Sapucai University '' , direct one author , measurement Progestogen Receptor ( PR ) Estrogen Receptor ( ER ) receptor well Bcl-2 protein . The remain endometrial tissue fix 10 % neutral buffer formalin 6-48 h process paraffin block . Histological immunohistochemical assessment Histology classification carry two pathologist . Both pathologist blind read different tissue section block-sample . After stain hematoxylin/eosin Schiff Periodic Acid ( PAS ) , specimen classify one follow category : tissue insufficient diagnosis , atrophic and/or inactive endometrium , proliferative weakly proliferative endometrium , progestogenic . Immunohistochemical detection Bcl-2 protein perform two pathologist . After antigen retrieval block non-specific site normal serum use Avidin/Biotin Blocking kit ( Vector Laboratories , Inc , California , USA ) , section incubate overnight 4º Celsius anti-Bcl-2 mouse monoclonal antibody ( 1:100 , Clone 124 , DAKO , Denmark ) . The tissue-bound antibody incubate 30 min room temperature Envision System . Staining visualize use Envision ( Kit N1587 , DAKO , Denmark ) . The cellular staining pattern antibody cytoplasmic . The presence ER PR detect describe previously . The cellular staining pattern antibody nuclear . A breast cancer specimen use positive control steroid receptor . Examinations photography perform use `` Axioskop 40 - Zeiss '' light microscope equip Canon™ D30 digital camera ( Tokyo , Japan ) video monitor ( LG 14 '' LCD ) accord procedure Pathology Department Santa Casa Sao Paulo Medical School , Sao Paulo , Brazil . The morphometric technique immunohistochemistry quantification do aid Neubauer graduate chamber . This consist glass slide , thicker regular slide , grid design divide square know dimension , visualize optical microscope . The Neubauer count chamber divide 9 large square , 1 mm side , mean triple line ( thus area large square= 1 mm² ) . Each large square contain 16 ( 4 x 4 ) medium-size square . Each medium size square divide triple line 25 ( 5 x 5 ) small square , side length 1/5 mm . Thus , area individual small square 0.05 x 0.05 mm= 0.0025 mm² 0.1 mm deep . The image observe microscope lens capture video camera display choose monitor . The Neubauer chamber place optical microscope , use objective magnifies original size object 400x magnification elect researcher . Finally , area high magnification field ( 400x magnification ) estimate mm² count total number individual small 0.0025 mm² square chamber within magnification area chosen . The total area high magnification correspond 0.094 mm² . Using approach , section prepare immunohistochemical method evaluate light microscope . The number cell study count 400x magnification . A 10-field count perform different situation evaluate . The mean number cell present 10-field count represent area 0.094 mm² . By mean simple rule three , number cell convert 1 mm² count . The cell count express numerical density , i.e . number positive cell per square millimeter epithelium . The number Bcl-2-positive cell immunoreactivity PR ER expression quantify manually two trained observer , blind experiment , evaluate separately glandular stromal cell . The immunohistochemical staining index ( numerical density ) define mean number positive immunoexpression cell per mm² , calculate 10 different field . Statistical analysis Statistical analysis perform use `` StatistiXL Package™ '' ( Statistical Power Microsoft Excel version 1.8 , 2007 ) . Differences demographic parameter , immunohistochemical stain index ER , PR Bcl-2 protein expression ( numerical density ) , well baseline treatment end-point endometrial thickness , analyze pair Student 's t-test different group . The relationship ER , PR Bcl-2 protein expression stroma glandular epithelium analyze use Spearman 's test . Statistical significance set p &lt; 0.05 . Data express mean + standard deviation ( SD ) .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<criteria>Healthy postmenopausal woman , amenorrheic 110 year , age 4560 year use follicle stimulate hormone &gt; 30 mIU/mL , participate study . In subject , menopausal status confirm level serum follicle stimulate hormone estradiol postmenopausal range . Inclusion criterion : intact uterus , washout period 8 week oral estrogen without progestogen , androgen , selective estrogen receptor modulators ( SERMs ) , four week transdermal local sex steroid , 20 week injection medroxyprogesterone acetate ( MPA ) contain contraceptive . neoplastic , metabolic infectious disease , uterine size great consistent 12week gestation , abnormality bimanual pelvic examination , concomitant use hormonal drug , body mass index ( BMI ) &gt; 30 kg/m2 , cigarette smoke endometrial thickness &gt; 5 mm presence endometrial abnormality transvaginal ultrasound ( TVUS ) . No subject present past history venous thrombosis , cerebrovascular cardiovascular disease , woman exclude condition could alter pharmacokinetics hypersensitivity drospirenone/estradiol tibolone .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>menopause</keyword>
	<keyword>drospirenone</keyword>
	<keyword>tibolone</keyword>
	<keyword>Bcl-2</keyword>
	<keyword>steroid receptor</keyword>
</DOC>